[Form 4] TEVA PHARMACEUTICAL INDUSTRIES LTD Insider Trading Activity

Rhea-AI Filing Summary

TEVA PHARMACEUTICAL INDUSTRIES LTD officer Mark Sabag reported equity compensation activity involving restricted share units and ordinary shares. On March 4, 2026, he exercised restricted share units into 33,512 ordinary shares and 18,601 ordinary shares at a price of zero per share, increasing his direct holdings. He also received a new grant of 30,385 restricted share units, scheduled to vest in annual installments from March 4, 2027 through March 4, 2030. Each restricted share unit represents a right to one ordinary share or its cash value, and the ordinary shares may be represented by American Depositary Shares.

Insider Trade Summary

52,113 shares exercised/converted

Mixed 5 txns

Insider Sabag Mark

Role See "Remarks"

Type	Security	Shares	Price	Value
Exercise	Restricted Share Units	33,512	$0.00	--
Exercise	Restricted Share Units	18,601	$0.00	--
Grant/Award	Restricted Share Units	30,385	$0.00	--
Exercise	Ordinary Shares	33,512	$0.00	--
Exercise	Ordinary Shares	18,601	$0.00	--

Holdings After Transaction: Restricted Share Units — 0 shares (Direct); Ordinary Shares — 252,718 shares (Direct)

Footnotes (1)

1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Restricted share units were granted on March 4, 2022, with 33,512 vested on each of March 4, 2023, March 4, 2024, March 4, 2025 and March 4, 2026. Restricted share units were granted on March 4, 2024, with 18,601 vested on each of March 4, 2025 and March 4, 2026, and 18,601 vesting on each of March 4, 2027 and March 4, 2028. Restricted share units were granted on March 4, 2026, with 7,596 vesting on each of March 4, 2027, March 4, 2028 and March 4, 2029, and 7,597 vesting on March 4, 2030.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 03/06/2026 - 04:13 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sabag Mark

(Last) (First) (Middle)

C/O TEVA PHARMACEUTICAL INDUSTRIES LTD.

124 DVORA HANEVI'A ST.,

(Street)

TEL AVIV L3 6944020

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
TEVA PHARMACEUTICAL INDUSTRIES LTD [ TEVA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See "Remarks"

3. Date of Earliest Transaction (Month/Day/Year)
03/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares(1)	03/04/2026		M		33,512	A	(2)	252,718	D
Ordinary Shares(1)	03/04/2026		M		18,601	A	(2)	271,319	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Share Units	(2)	03/04/2026		M			33,512	(3)	(3)	Ordinary Shares(1)	33,512	$0	0	D
Restricted Share Units	(2)	03/04/2026		M			18,601	(4)	(4)	Ordinary Shares(1)	18,601	$0	37,202	D
Restricted Share Units	(2)	03/04/2026		A		30,385		(5)	(5)	Ordinary Shares(1)	30,385	$0	30,385	D

Explanation of Responses:

1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

2. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

3. Restricted share units were granted on March 4, 2022, with 33,512 vested on each of March 4, 2023, March 4, 2024, March 4, 2025 and March 4, 2026.

4. Restricted share units were granted on March 4, 2024, with 18,601 vested on each of March 4, 2025 and March 4, 2026, and 18,601 vesting on each of March 4, 2027 and March 4, 2028.

5. Restricted share units were granted on March 4, 2026, with 7,596 vesting on each of March 4, 2027, March 4, 2028 and March 4, 2029, and 7,597 vesting on March 4, 2030.

Remarks:

Executive Vice President, International Markets Commercial

	/s/ Dov Bergwerk as attorney-in-fact for Mark Sabag	03/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.